An established practice in Queensland is the latest to join George & Matilda Eyecare (G&M) with more in the pipeline to be announced shortly, as the company celebrates its six-year anniversary. Read more
Designs For Vision prepares for big O-Show presence
Advanced imaging equipment for chronic eye disease will feature on the Designs For Vision (DFV) booth at OSHOW2022, however the ophthalmic equipment supplier is expecting significant interest in its array of myopia management diagnostics. Read more
Specsavers scheme sends recycled specs to Tonga
More than 100,000 spectacles collected through a Specsavers glasses recycling program have been donated to Tongans in need. Read more
Enduring products, enduring service
BOC Ophthalmic Instruments managing director TONY COSENTINO explains why he operates his distribution business on the knowledge that customers will ultimately remember him for the service, not the sale.
Independent optometry ownership: a sound investment
More younger practitioners are seeking fulfilment in their careers through independent optometry practice ownership. PHILIP ROSE explains how Eyecare Plus can help aspiring business owners with the transition. Read more
CooperVision steps up sustainability commitment in Australia and New Zealand
All CooperVision one-day contact lenses distributed in Australia and New Zealand are now plastic neutral, the company has announced. Read more
EyeQ-NOC acquires The Spectacle Site optometry group
The Spectacle Site has been acquired by EyeQ Optometrists-National Optical Care (NOC), with the deal comprising five Melbourne and Victorian practices and a Canberra location trading as Specialeyes. Read more
Fresh six-year MiYOSMART data unveiled at ARVO
New six-year data on Hoya Vision Care’s defocus myopia spectacle lens presented at ARVO 2022 has answered key questions over rebounding effects and the lens’ ability to sustain its myopia controlling effect over time. Read more
Prof Robyn Guymer to head up new 2RT study for iAMD
Adelaide-based Nova Eye Medical says it has navigated a time-consuming and complex series of conversations with the US Food and Drug Administration (FDA) to pave a clear approval pathway for its pioneering 2RT laser system for selected intermediate age-related macular degeneration (iAMD) patients. Read more
Bausch + Lomb eyes AU$1.2 billion in IPO
Ophthalmic giant Bausch + Lomb (B+L), which is being spun-off from its parent as a pure-play eye health company, has filed to raise up to US$840 million (AU$1.2 billion) in an initial public offering (IPO). Read more